Results 51 to 60 of about 108,133 (341)

An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders

Nature Mental Health
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel drugs approved for diabetes and obesity. They are acknowledged as a major scientific breakthrough.
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, Maxime Taquet, A. Adler, I. Koychev, R. Upthegrove, Marco Solmi, R. McCutcheon, T. Pillinger, Phil Cowen, Catherine J. Harmer   +11 more
semanticscholar   +1 more source

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

Nature Communications, 2022
Glucagon-like peptide-1 receptor (GLP1R) agonists are used to treat type 2 diabetes (T2D), and polyagonists targeting multiple hormone receptors are investigated as potential therapeutics for T2D.
Hongwei Jiang, Shuguang Pang, Yawei Zhang, Ting Yu, Meng Liu, Huan Deng, Li Li, Liqi Feng, Baili Song, Han Han-Zhang, Qingyang Ma, Lei Qian, Wenying Yang   +12 more
doaj   +1 more source

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

Molecular Metabolism, 2022
Objective: Pharmacological strategies that engage multiple mechanisms-of-action have demonstrated synergistic benefits for metabolic disease in preclinical models.
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, Bhavesh Premdjee, Karina Rahr Hjøllund, Yantao He, Ann Maria Kruse Hansen, Anette K. Olsen, Diego Perez-Tilve, Richard D. DiMarchi, Brian Finan   +10 more
doaj   +1 more source

G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets [PDF]

, 2014
It is becoming evident that nutrients and metabolic intermediates derived from such nutrients regulate cellular function by activating a number of cell-surface G-protein coupled receptors (GPCRs).
Brian D. Hudson, Graeme Milligan, Hannah Murdoch, Hoveyda, Ma, Saniere, Trond Ulven   +6 more
core   +2 more sources

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

Therapeutic Advances in Endocrinology and Metabolism
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have emerged as promising therapeutic agents with potent anti-inflammatory properties and diverse clinical implications.
S. Alharbi
semanticscholar   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management

Advances in Medicine, 2023
Rates of obesity have risen over the past few decades. Subsequently, the popularity of the pharmaceutical weight-loss drug market has grown over the past few years to meet growing demand. Among the most commonly prescribed drugs for weight management, many are glucagon-like peptide-1 receptor agonists (GLP-1 agonists) which are also utilized for the ...
Magda Wojtara, Ashmita Mazumder, Yusra Syeda, Nikodem Mozgała   +3 more
openaire   +2 more sources

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

The photoswitchable cannabinoid azo‐HU308 enables optical control of Ca2+ dynamics in INS‐1 β‐cells via off‐target effects on TRPC channels

FEBS Open Bio, EarlyView.
Light activation of the photoswitchable cannabinoid ligand azo‐HU308 triggers Ca2+ influx in pancreatic β‐cells through TRPC channels, independent of CB2 cannabinoid receptors. This reveals a non‐GPCR pathway for cannabinoid modulation of β‐cell Ca2+ dynamics and establishes azo‐HU308 as an optical tool to study cannabinoid signaling through TRP ...
Alexander E. G. Viray, James A. Frank
wiley   +1 more source

Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents [PDF]

, 2017
peer-reviewedThe gut hormone glucagon-like peptide (GLP)-1 and its analogues represent a new generation of anti-diabetic drugs, which have also demonstrated propensity to modulate host lipid metabolism.
Cryan, John F., Dinan, Timothy G., Kent, Robert M., Mandal, Rupasri, Murphy, Kiera, O’Connor, Paula M., Patterson, Elaine, Peterson, Veronica L., Ross, R Paul, Ryan, Paul M, Seeley, Randy J., Stack, Helena, STANTON, CATHERINE, Wishart, David S.   +13 more
core   +5 more sources

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

Molecular Metabolism, 2021
Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists are approved to treat type 2 diabetes and obesity. They elicit robust improvements in glycemic control and weight loss, combined with cardioprotection in individuals at risk of or with pre ...
Laurie L. Baggio, Daniel J. Drucker
doaj   +1 more source